Qualigen Surges 80% As QN-302 Shows Potential Preclinical Mechanism Of Action Against Prostate, Pancreatic Cancers


Qualigen Therapeutics Inc QLGN shares are surging after highlighting posters at the American Association of Cancer Research (AACR).

  • QN-302 showed potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo metastatic prostate cancer model.
  • It demonstrated bioavailability and toleration at therapeutic doses in a prostate cancer cell line, PC3, derived from castration-resistant prostate cancer.
  • The in vivo study, which included the commonly used drug abiraterone, showed that QN-302 had statistically significant anti-tumor activity in this model (p=0.0008) relative to the controls and was superior to abiraterone.
  • In another poster, QN-302 exhibited substantial anti-tumor activity in three patient-derived xenograft (PDX) models for pancreatic ductal adenocarcinoma (PDAC)
  • In three of these models, significant changes in tumor growth were observed in those receiving QN-302, together with good tolerance and bioavailability at therapeutic doses. 
  • Price Action: QLGN shares are up 82.1% at $1.11 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPreclinical Phasewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!